◀ Back to RAF1
JAK3 — RAF1
Pathways - manually collected, often from reviews:
-
NCI Pathway Database IL2-mediated signaling events:
RAF1 (RAF1)
→
IL2/IL2R alpha/beta/gamma/JAK1/LCK/JAK3/SHC/GRB2/SOS1/GAB2/SHP2/PI3K complex (IL2RA-IL2RB-IL2RG-IL2-JAK1-LCK-JAK3-SHC1-GRB2-SOS1-GAB2-PTPN11-PIK3CA-PIK3R1)
(modification, activates)
Blanchard et al., Oncogene 2000, Lundin Brockdorff et al., Cytokine 2002, Karnitz et al., Mol Cell Biol 1995
Evidence: mutant phenotype, other species
-
NCI Pathway Database SHP2 signaling:
RAF1 (RAF1)
→
IL2/IL2R alpha/beta/gamma/JAK1/LCK/JAK3/SHC/GRB2/SOS1/GAB2/SHP2/PI3K complex (IL2RA-IL2RB-IL2RG-IL2-JAK1-LCK-JAK3-SHC1-GRB2-SOS1-GAB2-PTPN11-PIK3CA-PIK3R1)
(modification, activates)
Blanchard et al., Oncogene 2000, Lundin Brockdorff et al., Cytokine 2002, Karnitz et al., Mol Cell Biol 1995
Evidence: mutant phenotype
Text-mined interactions from Literome
Niculescu et al., Immunopharmacology 1999
:
Therefore,
JAK1 activity may be
involved in activation of
Raf-1 and ERK1 via G proteins activated by C5b-9
Reiterer et al., Cell cycle (Georgetown, Tex.) 2010
(Genomic Instability) :
GW5074 also inhibited JAK inhibitor induced appearance of nuclear phosphorylated
RAF-1 ( pS621RAF ) and MEK ; and it
inhibited the
JAK inhibitor induced co-immunoprecipitation of nuclear RAF-1 and MEK